News Release

Printer Friendly Version View printer-friendly version << Back
ProQR Announces Proposed Public Offering of Ordinary Shares

13 November 2017 at 4:01 PM EST

LEIDEN, the Netherlands, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it intends to offer and sell its ordinary shares in an underwritten public offering.  All of the shares are being offered by ProQR.  In addition, in the public offering, ProQR expects to grant the underwriters a 30-day option to purchase additional ordinary shares, on the same terms and conditions.  Concurrently with the underwritten public offering, ProQR is conducting a registered direct offering.  Both offerings are subject to market conditions and other conditions, and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offering.

ProQR intends to use the net proceeds from both offerings to fund its clinical trials, ongoing research and development activities and for working capital and other general corporate purposes.

H.C. Wainwright & Co. is acting as sole book-running manager for the public offering, with National Securities Corporation acting as co-manager.  The registered direct offering is being made without an underwriter or a placement agent.

A shelf registration statement relating to the offered ordinary shares was filed with the Securities and Exchange Commission (SEC) on October 2, 2015, which was declared effective on October 19, 2015.  A preliminary prospectus supplement related to the public offering has been filed with the SEC and is available on the SEC's website, located at  Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the public offering may be obtained from H.C. Wainwright & Co., LLC at 430 Park Avenue, 4th Floor, New York, New York 10022, or by e-mail: or by telephone: 646-975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*


This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements about the completion, timing and size of the proposed offerings of ProQR’s ordinary shares, and the use of proceeds therefrom. These forward-looking statements involve risks and uncertainties, many of which are beyond ProQR’s control, including risk and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed offerings. There can be no assurance that ProQR will be able to complete the proposed offerings on the anticipated terms, or at all. Applicable risks also include those that are included in ProQR’s preliminary prospectus supplement and accompanying prospectus filed with the SEC for the proposed public offering, including the documents incorporated by reference therein, which include ProQR’s Annual Report on Form 20-F for the year ended December 31, 2016, and any subsequent SEC filings. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.:
Investor Contact:
Bonnie Ortega
T: +1 858 245 3983 

Source: ProQR Therapeutics N.V.